Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Receivables: 2016-2025

Historic Receivables for UroGen Pharma (URGN) over the last 7 years, with Sep 2025 value amounting to $19.7 million.

  • UroGen Pharma's Receivables fell 13.59% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.3 million, marking a year-over-year increase of 13.57%. This contributed to the annual value of $20.3 million for FY2024, which is 31.46% up from last year.
  • UroGen Pharma's Receivables amounted to $19.7 million in Q3 2025, which was up 0.27% from $19.6 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Receivables ranged from a high of $22.8 million in Q3 2024 and a low of $6.3 million during Q1 2021.
  • Over the past 3 years, UroGen Pharma's median Receivables value was $17.4 million (recorded in 2024), while the average stood at $17.3 million.
  • Per our database at Business Quant, UroGen Pharma's Receivables surged by 2,266.17% in 2021 and then declined by 13.59% in 2025.
  • Over the past 5 years, UroGen Pharma's Receivables (Quarterly) stood at $11.7 million in 2021, then grew by 8.42% to $12.7 million in 2022, then increased by 21.56% to $15.4 million in 2023, then skyrocketed by 31.46% to $20.3 million in 2024, then dropped by 13.59% to $19.7 million in 2025.
  • Its Receivables was $19.7 million in Q3 2025, compared to $19.6 million in Q2 2025 and $19.6 million in Q1 2025.